Labcorp Holdings Inc. (LH) KPIs and segments
Close on Nov 17, 2026Market cap $29.90BP/E 30.2Yield 0.78%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Labcorp · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Labcorp: 49 chỉ số vận hành, trong đó có Diagnostics Total Requisition Volume Growth, Diagnostics Total Price/Mix Change (YoY) và Diagnostics Total Revenue Growth (YoY), lấy từ 98 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diagnostics($M) | 2,949 | 2,901 | 2,762 | 2,729 | 2,770 | 2,749 | 2,630 | 2,586 | 2,554 | 2,525 | 2,480 | 2,347 | |
Biopharma Laboratory Services($M) | 867 | 836 | 781 | 793 | 799 | 785 | 721 | 767 | 738 | 707 | 711 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Diagnostics($M) | 492 | 523 | 459 | 419 | 450 | 483 | 428 | 360 | 387 | 442 | 418 | 354 | |
Biopharma Laboratory Services($M) | 159 | 142 | 121 | 136 | 132 | 123 | 107 | 131 | 121 | 107 | 99.9 | ||
Corporate Segment($M) | -154 | -130 | -117 | -100 | -111 | -139 | -132 | -189 | -173 | -180 | -129 | -174 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1 | |||||||||||||
Diagnostics Total Requisition Volume Growth (YoY)(%)3 | 4.8% | 3.0% | 2.5% | 2.2% | 4.7% | 4.9% | 3.0% | 6.8% | 5.1% | 3.4% | 2.4% | ||
Organic Requisition Volume Growth (YoY)(%) | 3.1% | 1.8% | 1.1% | 1.1% | 3.5% | 3.4% | 0.9% | 4.0% | 2.2% | 1.2% | 0.3% | ||
Acquisition Volume Contribution, Net of Divestitures (YoY)(%) | 1.6% | 1.3% | 1.4% | 1.1% | 1.2% | 1.5% | 2.1% | 2.8% | 2.8% | 2.2% | 2.1% | ||
Foreign Currency Impact on Requisition Volume (YoY)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||
Diagnostics Total Price/Mix Change (YoY)(%)3 | 1.7% | 2.5% | 2.6% | 3.3% | 3.7% | 4.0% | 3.0% | 3.4% | 3.8% | ||||
Organic Price/Mix Change (YoY)(%) | 1.3% | 1.8% | 1.8% | 3.0% | 2.8% | 1.1% | 0.7% | 1.1% | 2.7% | ||||
Acquisition Price/Mix Impact, Net of Divestitures (YoY)(%) | 0.5% | 0.6% | 0.6% | 0.3% | 1.0% | 3.0% | 2.6% | 2.4% | 1.2% | ||||
Foreign Currency Impact on Price/Mix (YoY)(%) | -0.1% | 0.0% | 0.2% | 0.0% | 0.0% | -0.1% | -0.3% | -0.1% | -0.1% | ||||
Diagnostics Total Revenue Growth (YoY)(%)2 | 6.5% | 5.5% | 5.0% | 5.5% | 8.5% | 8.9% | 6.0% | 10.2% | 8.9% | ||||
Diagnostics Organic Revenue Growth (YoY)(%) | 4.4% | 3.6% | 2.9% | 4.1% | 6.3% | 4.5% | 1.6% | 5.1% | 5.0% | ||||
Diagnostics Acquisition Revenue Contribution, Net of Divestitures (YoY)(%) | 2.2% | 1.9% | 2.0% | 1.5% | 2.2% | 4.5% | 4.7% | 5.2% | 4.0% | ||||
BLS Ending Backlog($M)2 | 8,920 | 8,730 | 8,640 | 8,720 | 8,580 | 8,710 | 8,180 | 7,990 | 8,140 | ||||
Next 12-Month Forecast Backlog Conversion($M) | 2,820 | 2,750 | 2,690 | 2,660 | 2,660 | 2,710 | 2,560 | 2,530 | 2,590 | ||||
BLS Ending Backlog Growth (YoY)(%) | 3.9% | 0.2% | 5.6% | 9.2% | 5.4% | 10.0% | 3.5% | -3.2% | 4.6% | ||||
BLS Trailing 12-Month Net Orders($M) | 3,590 | 3,320 | 3,290 | 3,370 | 3,340 | 3,340 | 3,150 | 2,910 | 2,900 | 2,820 | 2,890 | ||
BLS Trailing 12-Month Book-to-Bill Ratio(×)1 | 1.10 | 1.03 | 1.04 | 1.09 | 1.09 | 1.11 | 1.07 | 1.00 | 1.00 | 1.04 | |||
BLS Quarterly Book-to-Bill Ratio(×) | 1.13 | 1.14 | 0.94 | 1.16 | 0.89 | 1.18 | |||||||
BLS Total Revenue Growth (YoY)(%)4 | 8.5% | 6.5% | 8.2% | 3.4% | 8.3% | 11.0% | 1.5% | 10.4% | 2.6% | ||||
Central Laboratories Revenue Growth — Reported (YoY)(%)1 | 11.5% | 9.8% | 11.3% | 11.1% | 10.3% | 7.5% | 0.3% | 9.6% | 9.4% | ||||
Central Laboratories Revenue Growth — Organic Constant Currency (YoY)(%) | 11.3% | 7.6% | 4.9% | 7.7% | 4.0% | ||||||||
Early Development Research Laboratories Revenue Growth — Reported (YoY)(%)1 | 0.4% | -1.4% | 0.6% | -13.5% | 3.3% | 20.4% | 4.4% | 12.3% | |||||
Early Development Revenue Growth — Organic Constant Currency (YoY)(%) | 5.0% | 2.7% | 0.7% | -15.1% | 1.1% | 18.0% | |||||||
BLS Organic Revenue Growth (YoY)(%) | 9.6% | 6.2% | 3.7% | 0.6% | 5.3% | 7.8% | 2.6% | 8.9% | 2.0% | ||||
BLS Foreign Currency Translation Impact (YoY)(%) | -0.3% | 1.8% | 5.5% | 2.8% | 3.0% | 3.2% | -1.1% | 1.5% | 0.6% | ||||
Diagnostics Share of Consolidated Revenue(%)4 | 78.0% | 78.0% | 78.0% | 78.0% | 78.0% | 78.0% | |||||||
Third-Party Payers / Managed Care (% of Consolidated Revenue)(%) | 37.0% | 37.0% | 37.0% | 36.0% | 36.0% | 36.0% | |||||||
Clients — Physicians, Hospitals & Health Systems (% of Consolidated Revenue)(%) | 23.0% | 23.0% | 23.0% | 24.0% | 24.0% | 24.0% | |||||||
Patients — Self-Pay & Co-Insurance (% of Consolidated Revenue)(%) | 10.0% | 10.0% | 10.0% | 10.0% | 10.0% | 10.0% | |||||||
Medicare & Medicaid (% of Consolidated Revenue)(%) | 8.0% | 8.0% | 8.0% | 8.0% | 8.0% | 8.0% | |||||||
Biopharma Laboratory Services Share of Consolidated Revenue(%)3 | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | |||||||
Biopharma Clients — North America (% of Consolidated Revenue)(%) | 9.0% | 8.0% | 8.0% | 9.0% | 9.0% | 9.0% | |||||||
Biopharma Clients — Europe (% of Consolidated Revenue)(%) | 9.0% | 10.0% | 10.0% | 9.0% | 9.0% | 9.0% | |||||||
Biopharma Clients — Rest of World (% of Consolidated Revenue)(%) | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | |||||||
United States Consolidated Revenue($M)1 | 3,169 | 3,096 | 2,914 | 2,969 | 2,932 | 2,814 | 2,738 | 2,699 | 2,655 | ||||
United States Share of Consolidated Revenue(%) | 83.2% | 83.0% | 82.4% | 83.3% | 83.1% | 84.1% | 83.4% | 83.8% | 83.6% | ||||
Diagnostics Laboratories Segment Revenue($M)5 | 2,949 | 2,901 | 2,762 | 2,729 | 2,770 | 2,749 | 2,630 | 2,586 | 2,554 | 2,525 | 2,480 | ||
Diagnostics — Labor Expense($M) | 1,286 | 1,223 | 1,188 | 1,208 | 1,201 | 1,155 | 1,124 | 1,164 | 1,146 | 1,073 | 1,056 | ||
Diagnostics — Laboratory Reagents & Supplies Expense($M) | 636 | 625 | 614 | 590 | 589 | 591 | 587 | 567 | 538 | 544 | 560 | ||
Diagnostics — Segment Depreciation Expense($M) | 70.8 | 68.1 | 63.8 | 65.3 | 66.4 | 65.4 | 61.7 | 69.1 | 65.1 | 63.1 | 61.7 | ||
Diagnostics — Other Segment Operating Expenses($M) | 466 | 462 | 438 | 446 | 463 | 454 | 430 | 427 | 417 | 403 | 384 | ||
Diagnostics — Segment Adjusted Operating Income($M)1 | 492 | 523 | 459 | 419 | 450 | 483 | 428 | 360 | 387 | 442 | 418 | ||
Diagnostics — Adjusted Operating Margin(%) | 16.7% | 18.0% | 16.6% | 15.4% | 16.3% | 17.6% | 16.3% | 13.9% | 15.2% | ||||
Biopharma Laboratory Services Segment Revenue($M)6 | 867 | 836 | 781 | 793 | 799 | 785 | 721 | 767 | 738 | 707 | 711 | ||
BLS — Labor Expense($M) | 320 | 313 | 309 | 316 | 314 | 302 | 290 | 296 | 293 | 286 | 290 | ||
BLS — Laboratory Supplies & Kit Expense($M) | 126 | 131 | 122 | 117 | 120 | 131 | 111 | 122 | 110 | 107 | 104 | ||
BLS — Clinical Trial Specimen & Kit Shipping Expense($M) | 130 | 122 | 111 | 104 | 102 | 98.2 | 95 | 94 | 93.7 | 89.7 | 88.4 | ||
BLS — Segment Depreciation Expense($M) | 28.4 | 27.7 | 28.6 | 29.4 | 29 | 29 | 28.6 | 29.6 | 31.5 | 30.3 | 31.2 | ||
BLS — Other Segment Operating Expenses($M) | 103 | 101 | 89.7 | 90.8 | 103 | 101 | 90 | 94.4 | 89 | 87.2 | 97.5 | ||
BLS — Segment Adjusted Operating Income($M)1 | 159 | 142 | 121 | 136 | 132 | 123 | 107 | 131 | 121 | 107 | 99.9 | ||
BLS — Adjusted Operating Margin(%) | 18.3% | 17.0% | 15.5% | 17.2% | 16.5% | 15.7% | 14.8% | 17.0% | 16.4% | ||||
General Corporate & Unallocated Expenses($M)1 | 154 | 130 | 117 | 100 | 111 | 139 | 132 | 189 | 173 | 180 | 129 | ||
Intercompany Segment Revenue Eliminations($M) | -5.60 | -5.80 | -5.10 | -5.70 | -5.20 | -6.30 | -5.80 | -23.8 | -9.20 | -11 | -14 | ||
Unbilled Services (Contract Assets), Gross($M)4 | 149 | 166 | 166 | 164 | 163 | 162 | 159 | 161 | 168 | 159 | 128 | 193 | |
Unbilled Services, Net — Current($M) | 146 | 162 | 157 | 156 | 162 | 151 | 153 | 166 | 158 | 120 | 185 | ||
Revenue Recognized from Beginning Unearned Revenue Balance($M) | 19 | 34.1 | 58.3 | 16 | 34.4 | 68.9 | 20.2 | 26.8 | 51 | ||||
Diagnostics Trade Accounts Receivable, Net($M) | 1,625 | 1,547 | 1,513 | 1,349 | |||||||||
BLS Trade Accounts Receivable, Gross($M)1 | 825 | 833 | 808 | 791 | |||||||||
BLS Allowance for Credit Losses($M) | 37.1 | 37.2 | 33 | 36.4 | |||||||||
Unconditional Purchase Commitments — Laboratory Reagents & Equipment($M)3 | 112 | 115 | 122 | 129 | |||||||||
Unconditional Purchase Commitments — Due Within 1 Year($M) | 4.80 | 20.9 | 27.8 | 34.7 | |||||||||
Unconditional Purchase Commitments — Due in Year 2($M) | 32.7 | 20.5 | 20.5 | 20.5 | |||||||||
Unconditional Purchase Commitments — Due in Year 3($M) | 74 | 74 | 74 | 74 | |||||||||
Operating Lease Liabilities — Noncurrent($M)3 | 675 | 661 | 657 | 683 | 692 | 713 | 696 | 676 | 701 | 643 | 625 | 649 | |
Operating Lease Liabilities — Current($M) | 183 | 180 | 183 | 191 | 187 | 186 | 183 | 185 | 184 | 182 | 171 | 166 | |
Finance Lease Liabilities — Noncurrent($M) | 61.1 | 61.6 | 62.2 | 63 | 64.3 | 65.6 | 66.5 | 74.3 | 75.2 | 76.9 | 77.1 | 78.6 | |
Finance Lease Liabilities — Current($M) | 5.20 | 4.70 | 4.60 | 4.60 | 4.50 | 4.30 | 4.80 | 6.10 | 6.30 | 6.70 | 6.40 | 6.40 | |
Identifiable Intangible Assets, Gross($M)8 | 6,197 | 6,092 | 5,977 | 5,887 | 5,771 | 5,629 | 5,511 | 5,433 | 5,444 | 5,150 | 5,149 | 5,058 | |
Accumulated Amortization of Intangible Assets($M) | 2,480 | 2,413 | 2,341 | 2,291 | 2,199 | 2,134 | 2,024 | 1,944 | 1,903 | 1,818 | 1,755 | 1,716 | |
Intangible Asset Amortization Expense($M) | 78.7 | 78.1 | 75.6 | 72.6 | 69.5 | 68.3 | 69.6 | 70.4 | 63.7 | 62.2 | 60.1 | ||
Estimated Future Amortization Expense — Year 1($M) | 81.2 | 152 | 223 | 290 | 76.3 | 142 | 208 | 272 | 71 | 125 | 183 | 235 | |
Estimated Future Amortization Expense — Year 2($M) | 308 | 297 | 288 | 277 | 281 | 268 | 266 | 261 | 260 | 237 | 237 | 226 | |
Estimated Future Amortization Expense — Year 3($M) | 300 | 290 | 280 | 269 | 268 | 255 | 254 | 248 | 251 | 228 | 228 | 217 | |
Estimated Future Amortization Expense — Year 4($M) | 287 | 277 | 267 | 256 | 260 | 247 | 246 | 241 | 240 | 217 | 217 | 206 | |
Estimated Future Amortization Expense — Year 5($M) | 279 | 268 | 259 | 247 | 247 | 235 | 232 | 227 | 232 | 209 | 209 | 197 | |
Estimated Future Amortization Expense — After Year 5($M) | 1,922 | 1,853 | 1,767 | 1,697 | 1,874 | 1,778 | 1,724 | 1,683 | 1,915 | 1,736 | 1,737 | 1,675 | |
Remaining Share Repurchase Authorization($M)1 | 1,379 | 379 | 732 | 830 | 1,055 | 1,080 | 1,280 | 1,280 | 1,355 | 430 | 532 | 530 | |
Common Shares Repurchased — Quarterly / Annual | 0.00 | 1.30 | 0.40 | 0.90 | 0.10 | 0.80 | 0.00 | 0.30 | 0.30 | ||||
Incremental Dilutive Shares from Equity Awards | 0.50 | 0.30 | 0.60 | 0.60 | 0.50 | 0.70 | 0.40 | 0.20 | 0.60 | ||||
U.S. Medical & Diagnostic Laboratories Industry Revenue — Census QSS (NAICS 6215)($M)3 | 20,528 | 19,569 | 19,997 | 19,677 | 19,718 | 18,722 | 19,104 | 18,893 | 18,483 | 17,963 | 17,943 | ||
U.S. Ambulatory Health Care Services Revenue — Census QSS (NAICS 621)($M) | 414,886 | 395,174 | 407,176 | 398,164 | 389,960 | 373,423 | 380,950 | 366,854 | 362,208 | 347,178 | 347,128 | ||
U.S. Outpatient Care Centers Revenue — Census QSS (NAICS 6214)($M) | 45,108 | 44,022 | 45,300 | 42,797 | 41,832 | 40,030 | 40,602 | 37,897 | 37,227 | 36,087 | 37,030 | ||
U.S. Hospitals Industry Revenue — Census QSS (NAICS 622)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
U.S. Personal Consumption Expenditures — Health Care Services (SAAR) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.90 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
ClinicalTrials.gov Registered Studies Referencing Labcorp / Covance / Monogram | 7.00 | 2.00 | 2.00 | 3.00 | 4.00 | 3.00 | 6.00 | 5.00 | 1.00 | 2.00 | 10.00 | 10.00 | |
Quest Diagnostics Inc. (DGX) — Revenue($M)1 | 3,097 | 3,043 | 2,895 | 2,806 | 2,816 | 2,761 | 2,652 | 2,621 | 2,488 | 2,397 | 2,366 | 2,288 | |
Quest Diagnostics Inc. (DGX) — Operating Income($M) | 479 | 459 | 399 | 386 | 386 | 438 | 346 | 361 | 330 | 355 | 300 | 267 | |
Fortrea Holdings Inc. (FTRE) — Revenue($M)1 | 692 | 678 | 636 | 660 | 701 | 710 | 651 | 697 | 675 | 662 | 662 | 710 | |
Fortrea Holdings Inc. (FTRE) — Operating Income($M) | 15 | 15 | -3 | -14 | -9 | -330 | -520 | -56 | -18 | -51 | -37 | -24 | |
Charles River Laboratories International (CRL) — Revenue($M)1 | 983 | 1,004 | 996 | 994 | 1,005 | 1,032 | 984 | 1,003 | 1,010 | 1,026 | 1,012 | 1,013 | |
Charles River Laboratories International (CRL) — Operating Income($M) | 203 | 120 | 120 | -283 | 134 | 100 | 75 | -168 | 117 | 152 | 126 | 133 | |
IQVIA Holdings Inc. (IQV) — Revenue($M)1 | 4,428 | 4,368 | 4,151 | 4,364 | 4,100 | 4,017 | 3,829 | 3,958 | 3,896 | 3,814 | 3,737 | 3,868 | |
IQVIA Holdings Inc. (IQV) — Operating Income($M) | 572 | 506 | 514 | 627 | 553 | 506 | 496 | 626 | 550 | 520 | 506 | 501 | |
Medpace Holdings, Inc. (MEDP) — Revenue($M)1 | 716 | 707 | 707 | 708 | 660 | 603 | 559 | 537 | 533 | 528 | 511 | 498 | |
Medpace Holdings, Inc. (MEDP) — Operating Income($M) | 166 | 147 | 142 | 153 | 142 | 126 | 114 | 125 | 112 | 105 | 104 | 87 | |
Exact Sciences Corp. (EXAS) — Revenue($M)1 | 878 | 851 | 811 | 707 | 713 | 709 | 699 | 638 | 647 | ||||
Exact Sciences Corp. (EXAS) — Operating Income($M) | -83 | -26 | -2 | -96 | -876 | -39 | -26 | -107 | -68 | ||||
Natera, Inc. (NTRA) — Revenue($M)1 | 794 | 753 | 697 | 665 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | |
Natera, Inc. (NTRA) — Operating Income($M) | -68 | -76 | -94 | -23 | -98 | -110 | -79 | -65 | -39 | -44 | -74 | -85 | |
Guardant Health, Inc. (GH) — Revenue($M)1 | 361 | 335 | 302 | 281 | 265 | 232 | 203 | 202 | 191 | 177 | 168 | 155 | |
Guardant Health, Inc. (GH) — Operating Income($M) | -133 | -129 | -121 | -121 | -99 | -106 | -111 | -126 | -117 | -101 | -100 | -198 | |
NeoGenomics, Inc. (NEO) — Revenue1 | |||||||||||||
NeoGenomics, Inc. (NEO) — Operating Income($M) | -8 | -10 | -18 | -13 | -27 | -48 | -28 | -18 | -21 | -22 | -31 | -19 | |
Consolidated Revenue($M) | 3,810 | 3,731 | 3,538 | 3,516 | 3,564 | 3,527 | 3,345 | 3,329 | 3,282 | 3,221 | 3,177 | 3,033 | |
Cost of Revenues($M) | 2,702 | 2,619 | 2,524 | 2,523 | 2,538 | 2,481 | 2,397 | 2,433 | 2,378 | 2,295 | 2,279 | 2,212 | |
Gross Profit($M) | 1,108 | 1,112 | 1,014 | 993 | 1,025 | 1,046 | 948 | 896 | 904 | 926 | 897 | 821 | |
Selling, General and Administrative Expenses($M) | 611 | 577 | 551 | 538 | 553 | 579 | 546 | 595 | 569 | 558 | 508 | 533 | |
Consolidated Operating Income($M) | 402 | 452 | 381 | 268 | 397 | 395 | 326 | 217 | 254 | 295 | 321 | -123 | |
Net Earnings Attributable to Labcorp Holdings Inc.($M)3 | 263 | 299 | 278 | 165 | 261 | 238 | 213 | 143 | 169 | 205 | 228 | -167 | |
Diluted Earnings Per Share($) | 3.22 | 3.64 | 3.35 | 3.12 | 2.84 | 2.52 | 2 | 2.43 | 2.69 | ||||
Weighted-Average Diluted Shares | 81.60 | 82.00 | 82.90 | 83.70 | 83.90 | 84.30 | 84.40 | 84.30 | 84.70 | ||||
Dividends Declared Per Common Share($) | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | |||
Operating Cash Flow($M)5 | 564 | 446 | 192 | 614 | 387 | 621 | 18.5 | 777 | 277 | 561 | -29.8 | 580 | |
Depreciation and Amortization($M) | 183 | 179 | 173 | 173 | 171 | 170 | 167 | 171 | 162 | 157 | 155 | 146 | |
Stock-Based Compensation($M) | 30.8 | 34.9 | 31.7 | 29.7 | 29.2 | 34.1 | 32.8 | 27.3 | 27 | 30.8 | 31.6 | 27 | |
Net Cash Paid for Acquisitions($M) | 256 | 226 | 202 | 258 | 261 | 10 | 53.5 | 87.8 | 458 | 33.9 | 259 | 155 | |
Common Stock Repurchased($M) | -0 | 354 | 98 | 225 | 25 | 200 | -0 | 75.1 | 75 | -9 | |||
Common Stock Dividends Paid($M) | 58.2 | 58.7 | 61.2 | 59.3 | 59.9 | 59.9 | 61.6 | 60.1 | 60.5 | 60.4 | 62.1 | 61.1 | |
Total Assets($M)6 | 18,925 | 18,532 | 19,087 | 18,393 | 18,262 | 18,060 | 17,604 | 18,379 | 18,613 | 16,712 | 16,531 | 16,725 | |
Cash and Cash Equivalents($M) | 262 | 142 | 981 | 532 | 598 | 647 | 369 | 1,519 | 1,517 | 265 | 99.3 | 537 | |
Accounts Receivable, Net($M) | 2,413 | 2,342 | 2,289 | 2,104 | 2,109 | 2,121 | 2,123 | 1,944 | 2,059 | 2,089 | 2,084 | 1,913 | |
Inventories($M) | 538 | 562 | 498 | 535 | 522 | 508 | 488 | 493 | 483 | 442 | 475 | 475 | |
Goodwill($M) | 7,177 | 7,030 | 6,955 | 6,790 | 6,682 | 6,551 | 6,421 | 6,370 | 6,482 | 6,220 | 6,219 | 6,143 | |
Intangible Assets, Net($M) | 3,717 | 3,678 | 3,636 | 3,596 | 3,571 | 3,494 | 3,487 | 3,489 | 3,541 | 3,332 | 3,394 | 3,342 | |
Total Shareholders' Equity($M) | 8,848 | 8,607 | 8,729 | 8,620 | 8,697 | 8,473 | 8,307 | 8,052 | 8,170 | 8,006 | 7,960 | 7,875 | |
14 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Labcorp Holdings Inc. operates on a calendar fiscal year ending December 31 (latest quarterly period: Q3 2026 ended September 30, 2026; latest annual period: FY2025 ended December 31, 2025).
- Segment architecture: Following the June 30, 2023 spin-off of its late-stage clinical CRO business into Fortrea Holdings Inc. (NASDAQ: FTRE), Labcorp operates two reportable segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS, comprising Central Laboratories and Early Development Research Laboratories).
- Derived cells are strictly limited to calendar period-splitting (`Q4 = full year (10-K) − nine months (10-Q)` for fourth-quarter segment expense lines and U.S. revenue, and `quarter = year-to-date − previous year-to-date` for cash-flow items).
- Constant-currency growth rates for BLS Central Laboratories and Early Development are retained alongside reported growth because management explicitly issues full-year sub-segment guidance on an organic constant-currency basis and FX translation averaged >250 bps across recent quarters.
Không hiện vì thiếu các kỳ gần đây (11)
- Annual Diagnostic Test Volume ('more than 700 million' / 'more than 750 million' tests per year in Form 10-K Item 1 & Investor Day) — disclosed strictly as an inequality bound rather than an exact point count.
- Patient Service Centers Count ('more than 2,200' PSCs including 'more than 400' Walgreens locations) — disclosed strictly as an inequality bound across Form 10-K and Investor Day presentations.
- In-Office Phlebotomists Count ('more than 6,800' phlebotomists located in client offices) — disclosed strictly as an inequality bound in Form 10-K Item 1.
- Global Employee Headcount ('nearly 70,000' FTEs in FY2024; 'nearly 71,000' FTEs in FY2025) — disclosed strictly as an inequality/approximate bound in Form 10-K Item 1.
- FDA Drug & Therapeutic Approvals Supported ('more than 75%' / 'more than 85%' of new FDA approvals) — disclosed strictly as an inequality bound.
- Absolute Scope 1 & Scope 2 GHG Emissions (tCO2e) and Total Waste Generated (metric tons) — available only through FY2024 from 2020–2024 Corporate Responsibility Reports because the 2025 Corporate Responsibility Report PDF on labcorp.com is behind HTTP 403 WAF protection (lacks FY2025 continuity).
- Monthly Average Price Paid Per Repurchased Share — discontinuous in months with zero share repurchases (including July–September 2026).
- Standalone Parent vs. Subsidiary Subtraction — Labcorp Holdings Inc. reports consolidated US GAAP statements and has no standalone parent operating statements; clinical CRO operations spun off into Fortrea Holdings Inc. (FTRE) in June 2023 are already segregated in discontinued operations.
- Diagnostics Laboratories — Volume, Price/Mix & Network › Diagnostics Total Revenue Growth (YoY) › Diagnostics Foreign Currency Translation Impact (YoY) (insufficient consecutive latest periods)
- U.S. Clinical Lab Macro Indicators, ClinicalTrials.gov & Peer Benchmarks › NeoGenomics, Inc. (NEO) — Revenue (insufficient consecutive latest periods)
- Consolidated Financial & Historical Segment Context (GAAP) › Consolidated Operating Income › Restructuring and Special Charges (insufficient consecutive latest periods)
Dữ liệu cập nhật 2026-11-06.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Diagnostics Laboratories — Volume, Price/Mix & Network
Biopharma Laboratory Services (BLS) — Backlog, Orders & Sub-Segments
Payer Mix, Geographic Share & Segment Cost Structure
- Diagnostics Share of Consolidated Revenue (%)6 kỳ
- Biopharma Laboratory Services Share of Consolidated Revenue (%)6 kỳ
- United States Consolidated Revenue ($M)21 kỳ
- Diagnostics Laboratories Segment Revenue ($M)11 kỳ
- Biopharma Laboratory Services Segment Revenue ($M)11 kỳ
- General Corporate & Unallocated Expenses ($M)11 kỳ
Contract Assets, Purchase Commitments, Leases & Intangibles
Share Repurchase Activity (Monthly & Quarterly) & Equity Plans
Global Workforce Demographics, Pay Ratio & Fleet Sustainability
U.S. Clinical Lab Macro Indicators, ClinicalTrials.gov & Peer Benchmarks
- U.S. Medical & Diagnostic Laboratories Industry Revenue — Census QSS (NAICS 6215) ($M)42 kỳ
- U.S. Producer Price Index — Medical Laboratories (PPI NAICS 621511)129 kỳ
- U.S. Consumer Price Index — Medical Care Services128 kỳ
- U.S. Ambulatory Health Care Services Employment129 kỳ
- U.S. Total Health Care & Social Assistance Employment129 kỳ
- U.S. Personal Consumption Expenditures — Health Care Services (SAAR)43 kỳ
- ClinicalTrials.gov Registered Studies Referencing Labcorp / Covance / Monogram43 kỳ
- Quest Diagnostics Inc. (DGX) — Revenue ($M)43 kỳ
- Fortrea Holdings Inc. (FTRE) — Revenue ($M)18 kỳ
- Charles River Laboratories International (CRL) — Revenue ($M)41 kỳ
- IQVIA Holdings Inc. (IQV) — Revenue ($M)43 kỳ
- Medpace Holdings, Inc. (MEDP) — Revenue ($M)43 kỳ
- Exact Sciences Corp. (EXAS) — Revenue ($M)36 kỳ
- Natera, Inc. (NTRA) — Revenue ($M)43 kỳ
- Guardant Health, Inc. (GH) — Revenue ($M)37 kỳ
- NeoGenomics, Inc. (NEO) — Revenue ($M)0 kỳ
Consolidated Financial & Historical Segment Context (GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Labcorp
- Form 10-K (2026-02-24) ↗
- Form 10-Q (2026-10-30) ↗
- Form 8-K (2026-10-28) ↗
- Form 8-K (2026-02-17) ↗
- Proxy Statement (DEF 14A) (2026-04-10) ↗
- ClinicalTrials.gov API v2 (U.S. National Library of Medicine) ↗
- Exact Sciences Corp. SEC 10-K (XBRL) ↗
- U.S. Census Bureau QSS / FRED (REV6215TAXABL144QNSA) ↗
- BLS / FRED (PCU621511621511) ↗
- BLS / FRED (CUSR0000SAM2) ↗
- BLS / FRED (CES6562100001) ↗
- BLS / FRED (CES6562000101) ↗
See a number that looks wrong?